VistaGen Therapeutics, Inc. Announces 3 Significant Publications Supporting The Use Of Embryonic Stem Cells For Drug Discovery And Development

BURLINGAME, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics Inc., a biopharmaceutical company pioneering the use of embryonic stem cells as proprietary biological systems for discovery and development of novel drugs for the treatment of diabetes and neurological diseases, announced today three recent publications highlighting important advances in the understanding of how embryonic stem cells can be efficiently and reproducibly differentiated into heart and liver cells. These advances are a result of the research efforts directed by Dr. Gordon Keller, a highly regarded international stem cell scientist, Director of the McEwen Center for Regenerative Medicine in Toronto and Chairman of VistaGen’s Scientific Advisory Board. VistaGen has an exclusive license to these stem cell technologies for all pharmaceutical drug discovery and screening applications.